NCT00939588View on ClinicalTrials.gov

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2009

Conditions
Hypertension
Interventions
DRUG

Aliskiren/ Valsartan

DRUG

Telmisartan/ Ramipril

Trial Locations (1)

Unknown

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00939588 - Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients | Biotech Hunter | Biotech Hunter